SparingVision is a clinical-stage genomic medicines company focused on developing innovative treatments for ocular diseases, particularly inherited retinal diseases (IRDs) such as Retinitis Pigmentosa and age-related macular degeneration
SparingVision is a clinical-stage genomic medicines company focused on developing innovative treatments for ocular diseases, particularly inherited retinal diseases (IRDs) such as Retinitis Pigmentosa and age-related macular degeneration. The company aims to move beyond single gene correction therapies to provide mutation-independent treatments.